Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
Phase 1
Completed
- Conditions
- Obesity and Overweight
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 88
- Registration Number
- NCT03707990
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Tempe, Arizona, United States
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Phase 3
Completed
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo (Semaglutide)
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 304
- Registration Number
- NCT03693430
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain
Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
- Conditions
- Haemophilia B
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10
- Registration Number
- NCT03690336
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2274
- Registration Number
- NCT03689374
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Trabzon, Turkey
A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 498
- Registration Number
- NCT03687827
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa
A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 662
- Registration Number
- NCT03674866
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Terrebonne, Quebec, Canada
Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy
Completed
- Conditions
- Growth Hormone Deficiency in Children
- Interventions
- Other: No treatment given
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 321
- Registration Number
- NCT03672617
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
Completed
- Conditions
- Haemophilia BHaemophilia A
- Interventions
- Other: No treatment given
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 563
- Registration Number
- NCT03660774
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Seattle, Washington, United States
Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity
Phase 1
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: Placebo (NNC9204-1706)
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT03661879
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 333
- Registration Number
- NCT03648281
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Örebro, Sweden
© Copyright 2025. All Rights Reserved by MedPath